CD45RA T Cells: Immune Marker for Naïve and Memory T Cell Regulation
Precision Enrichment for Immunotherapy & CAR-T Applications
CD45RA+ T cells form the backbone of immune system renewal — from naïve T cells to regulatory subsets — enabling safer, more effective clinical outcomes.
CD45RA is an isoform of the CD45 glycoprotein, a critical T cell marker widely expressed on naïve T lymphocytes. These CD45RA+ T cells are essential for initiating fresh immune responses. In immunophenotyping and flow cytometry, the presence of CD45RA helps classify immune cells into naïve, memory, and regulatory subsets, making it vital for both research and therapy.
CD45RA+ T Cells: Classification and Function
Naïve T Cells
CD45RA+ cells are primarily naïve T cells that respond to new antigens and drive primary immune defense.
Stem Cell-like Memory T Cells
A subset of CD45RA+ cells (T-SCM) combines stem cell-like renewal with long-term immune memory.
Regulatory T Cells (Tregs)
CD45RA expression marks naïve regulatory T cells (FoxP3 low), known for strong immunosuppressive activity.
Difference Between CD45RA+ and CD45RO+
| CD45RA+ | CD45RO+ |
|---|---|
| Naïve T Cells | Memory T Cells |
| Unexposed to antigens | Previously activated |
| High proliferative potential | Rapid response upon re-exposure |
Therapeutic Applications of CD45RA+ Cells
Immune Reset
CD45RA+ cells are used in immune reset therapies for autoimmune diseases like Multiple Sclerosis and Type 1 Diabetes.
Cancer Immunotherapy
Naïve CD45RA+ T cells are being applied in CAR-T cell therapy for enhanced persistence and expansion.
Regulatory T Cell Trials
CD45RA+ Tregs help prevent graft-versus-host disease (GvHD) after transplants.
Genestac's Role in CD45RA+ Enrichment
At Genestac Therapeutics, we specialize in sorting and enrichment of CD45RA+ T cells using FACS and MACS under GMP conditions.
Naïve T Cell-Based Immunotherapy
Providing a fresh, unprimed T cell pool for next-generation cell therapy.
Regulatory T Cell Trials
Selecting naïve Tregs to prevent immune rejection and graft-vs-host complications.
Autologous & Allogeneic CAR-T
Enriching the optimal T cell starting population for scalable CAR-T manufacturing.
CD45RA+ cells form the backbone of immune system renewal, from naïve T cells to regulatory subsets. They hold promise in cancer immunotherapy, autoimmune control, and immune reconstitution. With Genestac's precision enrichment, CD45RA+ cells are enabling safer, more effective clinical outcomes.
Frequently Asked Questions
Why is CD45RA important in immunotherapy?
CD45RA distinguishes naïve T cells from memory cells. Naïve CD45RA+ T cells have high proliferative potential and can be engineered into CAR-T cells with superior long-term persistence, making them an ideal starting population for adoptive cell therapies.
Can CD45RA+ cells be used in autoimmune diseases?
Yes. Naïve CD45RA+ Tregs are increasingly used in immune tolerance protocols for conditions like Type 1 Diabetes and inflammatory bowel disease. Their robust suppressive function after activation provides durable disease control without generalized immunosuppression.
What is the difference between CD45RA and CD45RO?
CD45RA is expressed on naïve, antigen-inexperienced T cells and naïve Tregs. CD45RO is expressed on activated or memory T cells that have already encountered an antigen. Together they allow immunophenotyping of the immune system's experience status.
How does Genestac use CD45RA+ enrichment?
We use FACS and MACS cell sorting to isolate high-purity CD45RA+ T cell populations from donor blood under GMP-certified conditions, supporting both research and direct clinical therapy manufacturing pipelines.
Start Your Healing Journey Today
Our specialists are ready to guide you through CD45RA+ enrichment protocols tailored to your clinical needs.
